Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958241 | 1.00 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL953947 | 1.00 | KMT2A (0.50) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Hydrochloric Acid SCHEMBL10869034 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505514 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Bromide SCHEMBL4505510 | 0.98 | KMT2A (0.49) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Maleic Acid SCHEMBL10360499 | 0.93 | HRH1 (0.44) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL5085962 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL1975758 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| Cadaverine Tartrate SCHEMBL1975759 | 0.92 | KMT2A (0.43) | KMT2AMEN1LMNACYP2D6HRH1 | |
| SCHEMBL8424910 | 0.91 | KEAP1 (0.43) | KMT2AMEN1LMNACYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | MEDICHEM, S.A. (ES) | 2008-12-18 | — | — | US | claimed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009125430-A2 | IMPROVED PROCESS FOR PRODUCING DARIFENACIN | MATRIX LABORATOIRES LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | MEDICHEM, S.A. (ES) | 2008-12-18 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-5233053-A | Pyrrolidine derivatives | PFIZER INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0505376-A1 | MUSCARINIC RECEPTOR ANTAGONISTS. | PFIZER LTD (GB) | 1992-09-30 | — | — | EP | disclosed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
| US-4260606-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4242261-A | REACTING AN A,A-DIPHENYL-A-N-HETEROCYCLIC ACETAMIDE WITH BROMINE AND AN ALKALI METAL ALKOXIDE AND HEATING | A. H. ROBINS COMPANY, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4133881-A | Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods | A. H. ROBINS COMPANY, INCORPORATED (US) | 1979-01-09 | — | — | US | disclosed |
| US-4002766-A | 1-R-3-PYRROLIDINYL-A,A-DIPHENYLACETAMIDES, -ACETONITRILES, AND -METHANES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
| US-4002766-A | 1-R-3-PYRROLIDINYL-A,A-DIPHENYLACETAMIDES, -ACETONITRILES, AND -METHANES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | KMT2A 3578/4885MEN1 2021/4885LMNA 2545/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | KMT2A 1552/4885MEN1 4673/4885LMNA 4555/4885 |
| US-20080312455-A1 | Method For Determining Enantiomeric Purity Of Darifenacin And Intermediates | OPRL1, ADRB3, ADRB1 | KMT2A 3137/4885MEN1 2474/4885LMNA 3411/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | KMT2A 3578/4885MEN1 2021/4885LMNA 2545/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KMT2A 1220/4885MEN1 3774/4885LMNA 4772/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | KMT2A 3578/4885MEN1 2021/4885LMNA 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.